Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$191 Mln
P/E Ratio
--
P/B Ratio
1.26
Industry P/E
--
Debt to Equity
0.17
ROE
-0.05 %
ROCE
-26.77 %
Div. Yield
0 %
Book Value
10.46
EPS
-3.83
CFO
$239.66 Mln
EBITDA
$234.00 Mln
Net Profit
$61.98 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
| -14.82 | -11.88 | -13.40 | -45.04 | -15.44 | -14.35 | -10.11 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
| -27.17 | -23.45 | -17.39 | -20.84 | -12.71 | 54.27 | -37.49 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint... solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730 Read more
President, CEO & Director
Dr. Cheryl Renee Blanchard Ph.D.
President, CEO & Director
Dr. Cheryl Renee Blanchard Ph.D.
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Anika Therapeutics Inc (ANIK) stood at $ 203 Mln as on 31-Dec-24
The share price of Anika Therapeutics Inc (ANIK) is $14.02 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Anika Therapeutics Inc (ANIK) has given a return of -15.44% in the last 3 years.
Anika Therapeutics Inc (ANIK) has a market capitalisation of $ 191 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Anika Therapeutics Inc (ANIK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Anika Therapeutics Inc (ANIK) and enter the required number of quantities and click on buy to purchase the shares of Anika Therapeutics Inc (ANIK).
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730
The CEO & director of Dr. Cheryl Renee Blanchard Ph.D.. is Anika Therapeutics Inc (ANIK), and CFO & Sr. VP is Dr. Cheryl Renee Blanchard Ph.D..
There is no promoter pledging in Anika Therapeutics Inc (ANIK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Anika Therapeutics Inc. (ANIK) | Ratios |
|---|---|
|
Return on equity(%)
|
-30.79
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-47.02
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Anika Therapeutics Inc (ANIK) was $0 Mln.
$0.55
(
